20.500.12556/DiRROS-12917 Immunohistochemistry of pulmonary biomarkers : a perspective from members of the pulmonary pathology society The use of immunohistochemistry for the determination of pulmonary carcinoma biomarkers is a well-established and powerful technique. Immunohistochemisty is readily available in pathology laboratories, is relatively easy to perform and assess, can provide clinically meaningful results very quickly, and is relatively inexpensive. Pulmonary predictive biomarkers provide results essential for timely and accurate therapeutic decision making; for patients with metastatic non-small cell lung cancer, predictive immunohistochemistry includes ALK, (ROS1, EGFR in Europe), and programmed death ligand-1 (PD-L1) testing. Handling along proper methodologic lines is needed to ensure patients receive the most accurate and representative test outcomes. pulmonary biomarkers immunohistochemistry pathology pljučni biomarkerji imunohistokemija patologija true false true College of American Pathologists Angleški jezik Ni določen © 2018 College of American Pathologists Neznano 2020-12-17 09:03:44 2020-12-17 09:03:45 2022-08-19 03:35:40 0000-00-00 00:00:00 2018 0 ZDA 0 Soavtorji: Timothy Craig Allen, Julien Adam, Dara L. Aisner, Mary Beth Beasley, Alain C. Borczuk, Philip T. Cagle, Vera Luiza Capelozzi, Wendy Cooper, Lida P. Hariri, Izidor Kern, Sylvie Lantuejoul, Ross Miller, Mari Mino-Kenudson, Teodora Radonic, Kirtee Raparia, Natasha Rekhtman, Sinchita Roy-Chowdhuri, Prudence Russell, Frank Schneider, Lynette M. Sholl, Ming Sound Tsao, Marina Vivero, Yasushi Yatabe; str. 408-419 iss. 3 Vol. 142 Mar. 2018 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616.2 0003-9985 10.5858/arpa.2017-0106-SA 33522905 253975 http://www.archivesofpathology.org/doi/pdf/10.5858/arpa.2017-0106-SA 1 https://dirros.openscience.si/Dokument.php?lang=slv&id=15889 Univerzitetna klinika za pljučne bolezni in alergijo Golnik 0 0 0